Bridging science & business in Spain’s biotech landscape – Podcast
Gate2Brain’s CEO, Meritxell Teixidó, recently took part in a conversation exploring how to turn biotechnology into an economic driver, sharing her vision on the opportunities and challenges of the Spanish innovation landscape.
The discussion, which also featured Esther Riambau, CEO of Oniria Therapeutics, brought together several biotech leaders to reflect on the differences between Spain and Denmark in transforming research into thriving biotech companies.
While Denmark has succeeded in creating a strong ecosystem that connects science, industry, and investors, Spain continues to face structural challenges such as limited early-stage funding, a weaker science–industry interface, and a culture that still separates academia from entrepreneurship.
To better understand both the obstacles and opportunities shaping Spain’s biotech landscape, the discussion brought together voices from Gate2Brain, Oniria Therapeutics, Ingulados, and the CSIC services network.
In this context, Meritxell Teixidó highlighted the importance of collaboration to strengthen the Spanish biotech sector:
“Biotechnology has enormous potential to drive sustainable growth,” said Teixidó. “Building bridges between research, investors and entrepreneurs is essential if we want to unlock that potential.”
At Gate2Brain, we believe that initiatives like this help build a more connected innovation ecosystem — one that transforms scientific excellence into impactful therapies and contributes to a stronger European biotechnology landscape.
